[
  {
    "account_name": "AstraZeneca",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 21.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subje | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Posit | trial_candidate: Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors",
    "best_fit_trial_title": "A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05850234",
    "best_urgency_trial_title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06542250",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "AstraZeneca",
    "total_score": 21.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06542250",
      "https://clinicaltrials.gov/study/NCT05877599",
      "https://clinicaltrials.gov/study/NCT06218914",
      "https://clinicaltrials.gov/study/NCT06005493",
      "https://clinicaltrials.gov/study/NCT07215585",
      "https://clinicaltrials.gov/study/NCT04594642",
      "https://clinicaltrials.gov/study/NCT07201558",
      "https://clinicaltrials.gov/study/NCT05850234"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "SecuraBio",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy",
    "best_fit_trial_title": "Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05044039",
    "best_urgency_trial_title": "Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05044039",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "SecuraBio",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05044039"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Legend Biotech USA Inc",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer",
    "best_fit_trial_title": "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05680922",
    "best_urgency_trial_title": "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05680922",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Legend Biotech USA Inc",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05680922"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Invectys",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanc",
    "best_fit_trial_title": "A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05672459",
    "best_urgency_trial_title": "A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05672459",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Invectys",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05672459"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Chongqing Precision Biotech Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE | trial_collaborator: CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases | trial_candidate: A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer",
    "best_fit_trial_title": "Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07318259",
    "best_urgency_trial_title": "Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07318259",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Chongqing Precision Biotech Co., Ltd",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07318259",
      "https://clinicaltrials.gov/study/NCT07247396",
      "https://clinicaltrials.gov/study/NCT06768151",
      "https://clinicaltrials.gov/study/NCT06056921"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Hebei Senlang Biotechnology Inc., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL",
    "best_fit_trial_title": "Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06880913",
    "best_urgency_trial_title": "Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06880913",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Hebei Senlang Biotechnology Inc., Ltd.",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06880913"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Tessa Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma",
    "best_fit_trial_title": "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04526834",
    "best_urgency_trial_title": "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04526834",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Tessa Therapeutics",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04526834"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Miltenyi Biomedicine GmbH",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: MB-dNPM1-TCR.1 in Relapsed/Refractory AML | trial_candidate: Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell N | trial_candidate: MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)",
    "best_fit_trial_title": "The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07020260",
    "best_urgency_trial_title": "MB-dNPM1-TCR.1 in Relapsed/Refractory AML",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06424340",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Miltenyi Biomedicine GmbH",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06424340",
      "https://clinicaltrials.gov/study/NCT06508931",
      "https://clinicaltrials.gov/study/NCT03853616",
      "https://clinicaltrials.gov/study/NCT07020260"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Incyte Corporation",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | trial_collaborator: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",
    "best_fit_trial_title": "Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05757219",
    "best_urgency_trial_title": "A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07195916",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Incyte Corporation",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07195916",
      "https://clinicaltrials.gov/study/NCT05757219"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Bristol-Myers Squibb",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_fit_trial_title": "French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04328298",
    "best_urgency_trial_title": "Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05621096",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bristol-Myers Squibb",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05621096",
      "https://clinicaltrials.gov/study/NCT04328298"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Shanghai Ming Ju Biotechnology Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | trial_candidate: CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | trial_collaborator: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors",
    "best_fit_trial_title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06149169",
    "best_urgency_trial_title": "CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06149169",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Shanghai Ming Ju Biotechnology Co., Ltd.",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06149169",
      "https://clinicaltrials.gov/study/NCT06479356",
      "https://clinicaltrials.gov/study/NCT06170294"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Bellicum Pharmaceuticals",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC",
    "best_fit_trial_title": "Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06096038",
    "best_urgency_trial_title": "Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06096038",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bellicum Pharmaceuticals",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06096038"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "UTC Therapeutics Inc.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma",
    "best_fit_trial_title": "CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05948033",
    "best_urgency_trial_title": "CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05948033",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "UTC Therapeutics Inc.",
    "total_score": 19.0,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05948033"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Pfizer",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 19.0,
    "fit_reason": "molecule match: elranatamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With D | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (M | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myelo",
    "best_fit_trial_title": "A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05623020",
    "best_urgency_trial_title": "A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05675449",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Pfizer",
    "total_score": 19.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05623020",
      "https://clinicaltrials.gov/study/NCT06152575",
      "https://clinicaltrials.gov/study/NCT05020236",
      "https://clinicaltrials.gov/study/NCT05675449",
      "https://clinicaltrials.gov/study/NCT05090566",
      "https://clinicaltrials.gov/study/NCT05317416",
      "https://clinicaltrials.gov/study/NCT04649359"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Imugene Limited",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: blinatumomab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refra | trial_candidate: A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Soli",
    "best_fit_trial_title": "A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06063317",
    "best_urgency_trial_title": "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT03666000",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Imugene Limited",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT03666000",
      "https://clinicaltrials.gov/study/NCT06063317"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Celgene Corporation",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: talquetamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap | trial_collaborator: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_title": "Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06348108",
    "best_urgency_trial_title": "Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06348108",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Celgene Corporation",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06220201",
      "https://clinicaltrials.gov/study/NCT06348108"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Amgen",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: blinatumomab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | trial_candidate: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Ca | trial_candidate: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer",
    "best_fit_trial_title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT03263572",
    "best_urgency_trial_title": "Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07061080",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Amgen",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07061080",
      "https://clinicaltrials.gov/study/NCT06555796",
      "https://clinicaltrials.gov/study/NCT04221542",
      "https://clinicaltrials.gov/study/NCT06613100",
      "https://clinicaltrials.gov/study/NCT05361395",
      "https://clinicaltrials.gov/study/NCT03319940",
      "https://clinicaltrials.gov/study/NCT03263572",
      "https://clinicaltrials.gov/study/NCT06814496"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Takeda",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: blinatumomab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myel | trial_collaborator: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi",
    "best_fit_trial_title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT03263572",
    "best_urgency_trial_title": "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT03263572",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Takeda",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06980480",
      "https://clinicaltrials.gov/study/NCT03263572"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Regeneron Pharmaceuticals",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: odronextamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who  | trial_candidate: Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in A",
    "best_fit_trial_title": "A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT02651662",
    "best_urgency_trial_title": "A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05092347",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Regeneron Pharmaceuticals",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05092347",
      "https://clinicaltrials.gov/study/NCT03761108",
      "https://clinicaltrials.gov/study/NCT05828511",
      "https://clinicaltrials.gov/study/NCT02651662",
      "https://clinicaltrials.gov/study/NCT05730036",
      "https://clinicaltrials.gov/study/NCT05137054",
      "https://clinicaltrials.gov/study/NCT03564340",
      "https://clinicaltrials.gov/study/NCT06091254"
    ],
    "score_details": {
      "trial_count": 11,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Janssen Pharmaceuticals",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: teclistamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Teclistamab-Daratumumab in AL Amyloidosis",
    "best_fit_trial_title": "Teclistamab-Daratumumab in AL Amyloidosis",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07110844",
    "best_urgency_trial_title": "Teclistamab-Daratumumab in AL Amyloidosis",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07110844",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Janssen Pharmaceuticals",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07110844"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Genmab",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: epcoritamab",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and",
    "best_fit_trial_title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05660967",
    "best_urgency_trial_title": "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05660967",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Genmab",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05660967",
      "https://clinicaltrials.gov/study/NCT04623541"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Eli Lilly and Company",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: mosunetuzumab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and | trial_collaborator: Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROM",
    "best_fit_trial_title": "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06948786",
    "best_urgency_trial_title": "Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06948786",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Eli Lilly and Company",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04623541",
      "https://clinicaltrials.gov/study/NCT06948786"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Janssen Research & Development, LLC",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: teclistamab",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed ",
    "best_fit_trial_title": "A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04557098",
    "best_urgency_trial_title": "A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04557098",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Janssen Research & Development, LLC",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04557098",
      "https://clinicaltrials.gov/study/NCT03399799",
      "https://clinicaltrials.gov/study/NCT03145181",
      "https://clinicaltrials.gov/study/NCT06348108"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Johnson & Johnson",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: teclistamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
    "best_fit_trial_title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05972135",
    "best_urgency_trial_title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05972135",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Johnson & Johnson",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05972135"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Cullinan Therapeutics Inc.",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "T cell engager / CD3 / bispecific trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupu | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Dis",
    "best_fit_trial_title": "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06613360",
    "best_urgency_trial_title": "CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05143996",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Cullinan Therapeutics Inc.",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05143996",
      "https://clinicaltrials.gov/study/NCT06613360",
      "https://clinicaltrials.gov/study/NCT07041099"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Genentech, Inc.",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: mosunetuzumab",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Agg | trial_collaborator: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High",
    "best_fit_trial_title": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05464329",
    "best_urgency_trial_title": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05464329",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Genentech, Inc.",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05464329",
      "https://clinicaltrials.gov/study/NCT06249191"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Pharmacyclics LLC.",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: blinatumomab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
    "best_fit_trial_title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT02997761",
    "best_urgency_trial_title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT02997761",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Pharmacyclics LLC.",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT02997761"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Janssen Pharmaceutical K.K.",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 17.0,
    "fit_reason": "molecule match: teclistamab",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_title": "A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04696809",
    "best_urgency_trial_title": "A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04696809",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Janssen Pharmaceutical K.K.",
    "total_score": 17.0,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04696809"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Bioray Laboratories",
    "fit": 5.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 16.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.",
    "best_fit_trial_title": "Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06485232",
    "best_urgency_trial_title": "Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "EARLY_PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06485232",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bioray Laboratories",
    "total_score": 16.0,
    "fit_score": 5.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06485232"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Gilead Sciences",
    "fit": 5.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 16.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_fit_trial_title": "French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04328298",
    "best_urgency_trial_title": "French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04328298",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Gilead Sciences",
    "total_score": 16.0,
    "fit_score": 5.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04328298"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Novartis",
    "fit": 5.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 16.0,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_fit_trial_title": "French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04328298",
    "best_urgency_trial_title": "French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04328298",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Novartis",
    "total_score": 16.0,
    "fit_score": 5.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04328298"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Corregene Biotechnology Co., Ltd",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | trial_candidate: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers",
    "best_fit_trial_title": "KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06767046",
    "best_urgency_trial_title": "KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06767046",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Corregene Biotechnology Co., Ltd",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06767046",
      "https://clinicaltrials.gov/study/NCT06358053"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Shanghai Ruiliyuan Biotechnology Co., Ltd.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors",
    "best_fit_trial_title": "HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06515314",
    "best_urgency_trial_title": "HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06515314",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Shanghai Ruiliyuan Biotechnology Co., Ltd.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06515314"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Neowise Biotechnology",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors | trial_collaborator: T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Adva | trial_collaborator: T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Adva",
    "best_fit_trial_title": "TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07266298",
    "best_urgency_trial_title": "TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07266298",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Neowise Biotechnology",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07266298",
      "https://clinicaltrials.gov/study/NCT06478251",
      "https://clinicaltrials.gov/study/NCT06484790",
      "https://clinicaltrials.gov/study/NCT06484556"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "SCG Cell Therapy Pte. Ltd.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | trial_candidate: A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | trial_candidate: Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma",
    "best_fit_trial_title": "A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06617000",
    "best_urgency_trial_title": "A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05417932",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "SCG Cell Therapy Pte. Ltd.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05417932",
      "https://clinicaltrials.gov/study/NCT06617000",
      "https://clinicaltrials.gov/study/NCT06505551"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Affini-T Therapeutics, Inc.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Recepto | trial_candidate: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Meta",
    "best_fit_trial_title": "Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06043713",
    "best_urgency_trial_title": "Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06043713",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Affini-T Therapeutics, Inc.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06043713",
      "https://clinicaltrials.gov/study/NCT06105021"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Lion TCR Pte. Ltd.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | trial_candidate: Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | trial_candidate: Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)",
    "best_fit_trial_title": "Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06961617",
    "best_urgency_trial_title": "Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06961617",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Lion TCR Pte. Ltd.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06961617",
      "https://clinicaltrials.gov/study/NCT05195294",
      "https://clinicaltrials.gov/study/NCT04745403"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Iovance Biotherapeutics, Inc.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | trial_collaborator: E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | trial_collaborator: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",
    "best_fit_trial_title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05639972",
    "best_urgency_trial_title": "E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05639972",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Iovance Biotherapeutics, Inc.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05639972",
      "https://clinicaltrials.gov/study/NCT05686226",
      "https://clinicaltrials.gov/study/NCT05483491"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Guangzhou FineImmune Biotechnology Co., LTD.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | trial_candidate: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors",
    "best_fit_trial_title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06942143",
    "best_urgency_trial_title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06942143",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Guangzhou FineImmune Biotechnology Co., LTD.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06942143",
      "https://clinicaltrials.gov/study/NCT03891706"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Celldex Therapeutics",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)",
    "best_fit_trial_title": "Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05349890",
    "best_urgency_trial_title": "Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05349890",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Celldex Therapeutics",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05349890"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "TScan Therapeutics, Inc.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable)  | trial_candidate: A Long Term Follow-up Study of TScan TCR-T Products | trial_candidate: A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Tra",
    "best_fit_trial_title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05973487",
    "best_urgency_trial_title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05973487",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "TScan Therapeutics, Inc.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05973487",
      "https://clinicaltrials.gov/study/NCT06976736",
      "https://clinicaltrials.gov/study/NCT05473910"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "TCRCure Biopharma Ltd.",
    "fit": 3.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 15.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors",
    "best_fit_trial_title": "NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05881525",
    "best_urgency_trial_title": "NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05881525",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "TCRCure Biopharma Ltd.",
    "total_score": 15.0,
    "fit_score": 3.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05881525"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Keymed Biosciences Co.Ltd",
    "fit": 4.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 14.0,
    "fit_reason": "T cell engager / CD3 / bispecific trial",
    "urgency_reason": "NOT_YET_RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma",
    "best_fit_trial_title": "BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "NA",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06745687",
    "best_urgency_trial_title": "BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "NA",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06745687",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Keymed Biosciences Co.Ltd",
    "total_score": 14.0,
    "fit_score": 4.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06745687"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Janssen Inc.",
    "fit": 4.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 14.0,
    "fit_reason": "molecule match: teclistamab",
    "urgency_reason": "RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Plan Development for Giving Teclistamab in the Outpatient Setting",
    "best_fit_trial_title": "Plan Development for Giving Teclistamab in the Outpatient Setting",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE4",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06251076",
    "best_urgency_trial_title": "Plan Development for Giving Teclistamab in the Outpatient Setting",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE4",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06251076",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Janssen Inc.",
    "total_score": 14.0,
    "fit_score": 4.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06251076"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Allogene Therapeutics",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
    "best_fit_trial_title": "Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04696731",
    "best_urgency_trial_title": "Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04696731",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Allogene Therapeutics",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04696731"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Kite, A Gilead Company",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma",
    "best_fit_trial_title": "Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06079164",
    "best_urgency_trial_title": "Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06079164",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Kite, A Gilead Company",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06079164"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap",
    "best_fit_trial_title": "A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06220201",
    "best_urgency_trial_title": "A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06220201",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06220201"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Nanjing Legend Biotech Co.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
    "best_fit_trial_title": "Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06395870",
    "best_urgency_trial_title": "Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06395870",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Nanjing Legend Biotech Co.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06395870"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
    "best_fit_trial_title": "PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07188610",
    "best_urgency_trial_title": "PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07188610",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07188610"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Cellectis S.A.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukem",
    "best_fit_trial_title": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT03190278",
    "best_urgency_trial_title": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT03190278",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Cellectis S.A.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT03190278"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Guangzhou Bio-gene Technology Co., Ltd",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "best_fit_trial_title": "Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06118788",
    "best_urgency_trial_title": "Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06118788",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Guangzhou Bio-gene Technology Co., Ltd",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06118788"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Curocell Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients",
    "best_fit_trial_title": "Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04836507",
    "best_urgency_trial_title": "Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04836507",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Curocell Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04836507"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Nanjing IASO Biotechnology Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies",
    "best_fit_trial_title": "IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07309900",
    "best_urgency_trial_title": "IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07309900",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Nanjing IASO Biotechnology Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07309900"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Hoffmann-La Roche",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Par",
    "best_fit_trial_title": "A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05535244",
    "best_urgency_trial_title": "A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05535244",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Hoffmann-La Roche",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05535244"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Beijing Immunochina Medical Science & Technology Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus",
    "best_fit_trial_title": "Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06852573",
    "best_urgency_trial_title": "Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06852573",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Beijing Immunochina Medical Science & Technology Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06852573"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Shine-On Biomedical Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors",
    "best_fit_trial_title": "A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07055594",
    "best_urgency_trial_title": "A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07055594",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Shine-On Biomedical Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07055594"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Excyte Biopharma Ltd",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus | trial_candidate: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012",
    "best_fit_trial_title": "A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06574568",
    "best_urgency_trial_title": "A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06574568",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Excyte Biopharma Ltd",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06574568",
      "https://clinicaltrials.gov/study/NCT07010835",
      "https://clinicaltrials.gov/study/NCT06565689"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Boehringer Ingelheim",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine  | trial_candidate: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That ",
    "best_fit_trial_title": "A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04429087",
    "best_urgency_trial_title": "A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04429087",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Boehringer Ingelheim",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04429087",
      "https://clinicaltrials.gov/study/NCT05916313"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Guangzhou Excelmab Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma",
    "best_fit_trial_title": "Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06021678",
    "best_urgency_trial_title": "Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06021678",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Guangzhou Excelmab Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06021678"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Clasp Therapeutics, Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation",
    "best_fit_trial_title": "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06778863",
    "best_urgency_trial_title": "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06778863",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Clasp Therapeutics, Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06778863"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "BeiGene",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | trial_candidate: A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors",
    "best_fit_trial_title": "A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06803680",
    "best_urgency_trial_title": "A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06803680",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "BeiGene",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04221542",
      "https://clinicaltrials.gov/study/NCT06803680"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma",
    "best_fit_trial_title": "A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06700395",
    "best_urgency_trial_title": "A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06700395",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06700395"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma",
    "best_fit_trial_title": "Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06829771",
    "best_urgency_trial_title": "Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06829771",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06829771"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Lyell Immunopharma, Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study of LYL314 in Aggressive Large B-Cell Lymphoma",
    "best_fit_trial_title": "Study of LYL314 in Aggressive Large B-Cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05826535",
    "best_urgency_trial_title": "Study of LYL314 in Aggressive Large B-Cell Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05826535",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Lyell Immunopharma, Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05826535"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Normunity AccelCo, Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors",
    "best_fit_trial_title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07182149",
    "best_urgency_trial_title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07182149",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Normunity AccelCo, Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07182149"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Candid Therapeutics",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants",
    "best_fit_trial_title": "Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07236411",
    "best_urgency_trial_title": "Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07236411",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Candid Therapeutics",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07236411"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Rondo Therapeutics",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid T",
    "best_fit_trial_title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07218003",
    "best_urgency_trial_title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07218003",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Rondo Therapeutics",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07218003"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Qilu Pharmaceutical Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus",
    "best_fit_trial_title": "A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07001839",
    "best_urgency_trial_title": "A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07001839",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Qilu Pharmaceutical Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07001839"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "EpimAb Biotherapeutics (Suzhou)Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma",
    "best_fit_trial_title": "First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05607498",
    "best_urgency_trial_title": "First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05607498",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "EpimAb Biotherapeutics (Suzhou)Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05607498"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)",
    "best_fit_trial_title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04471727",
    "best_urgency_trial_title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04471727",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04471727"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma",
    "best_fit_trial_title": "Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06854445",
    "best_urgency_trial_title": "Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06854445",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06854445"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Vironexis Biotherapeutics Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | trial_candidate: Gene Therapy for HER-Positive Cancer (SENTRY-HER2)",
    "best_fit_trial_title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06533579",
    "best_urgency_trial_title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06533579",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Vironexis Biotherapeutics Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06533579",
      "https://clinicaltrials.gov/study/NCT07192432"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Immunocore Ltd",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
    "best_fit_trial_title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT03070392",
    "best_urgency_trial_title": "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT03070392",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Immunocore Ltd",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT03070392"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Shandong Boan Biotechnology Co., Ltd",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of BA1202 in Patients With Advanced Solid Tumors",
    "best_fit_trial_title": "A Study of BA1202 in Patients With Advanced Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05909241",
    "best_urgency_trial_title": "A Study of BA1202 in Patients With Advanced Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05909241",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Shandong Boan Biotechnology Co., Ltd",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05909241"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "NaviFUS Corporation",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Gl",
    "best_fit_trial_title": "Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07343986",
    "best_urgency_trial_title": "Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07343986",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "NaviFUS Corporation",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07343986"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Genrix (Shanghai) Biopharmaceutical Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of GR1803 in Systemic Lupus Erythematosus",
    "best_fit_trial_title": "A Study of GR1803 in Systemic Lupus Erythematosus",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07348055",
    "best_urgency_trial_title": "A Study of GR1803 in Systemic Lupus Erythematosus",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07348055",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Genrix (Shanghai) Biopharmaceutical Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07348055"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Wuhan YZY Biopharma Co., Ltd.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC",
    "best_fit_trial_title": "A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05543330",
    "best_urgency_trial_title": "A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05543330",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Wuhan YZY Biopharma Co., Ltd.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05543330"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "GlaxoSmithKline",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)",
    "best_fit_trial_title": "A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07371468",
    "best_urgency_trial_title": "A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07371468",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "GlaxoSmithKline",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07371468"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Ono Pharmaceutical Co. Ltd",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma",
    "best_fit_trial_title": "Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05079282",
    "best_urgency_trial_title": "Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05079282",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Ono Pharmaceutical Co. Ltd",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05079282"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Ouro Medicines",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: OM336 in Seropositive Autoimmune Diseases",
    "best_fit_trial_title": "OM336 in Seropositive Autoimmune Diseases",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07229144",
    "best_urgency_trial_title": "OM336 in Seropositive Autoimmune Diseases",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07229144",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Ouro Medicines",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07229144"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "BioAtla, Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.",
    "best_fit_trial_title": "Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05808634",
    "best_urgency_trial_title": "Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05808634",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "BioAtla, Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05808634"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Medigene AG",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovar",
    "best_fit_trial_title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06748872",
    "best_urgency_trial_title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06748872",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Medigene AG",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06748872"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "BlueSphere Bio, Inc",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",
    "best_fit_trial_title": "BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06704152",
    "best_urgency_trial_title": "BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06704152",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "BlueSphere Bio, Inc",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06704152"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "HRYZ Biotech Co.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: HRYZ-T101 Injection for HPV18 Positive Solid Tumor",
    "best_fit_trial_title": "HRYZ-T101 Injection for HPV18 Positive Solid Tumor",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05952947",
    "best_urgency_trial_title": "HRYZ-T101 Injection for HPV18 Positive Solid Tumor",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05952947",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "HRYZ Biotech Co.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05952947"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Merck Sharp & Dohme LLC",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
    "best_fit_trial_title": "Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04201873",
    "best_urgency_trial_title": "Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04201873",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Merck Sharp & Dohme LLC",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04201873"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Oncovir, Inc.",
    "fit": 2.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 13.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
    "best_fit_trial_title": "Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04201873",
    "best_urgency_trial_title": "Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04201873",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Oncovir, Inc.",
    "total_score": 13.0,
    "fit_score": 2.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04201873"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "TCRx Therapeutics Co.Ltd",
    "fit": 3.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 12.0,
    "fit_reason": "cell therapy / TCR trial",
    "urgency_reason": "RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: KSX01-TCRT Injection Project in Solid Tumors | trial_candidate: KSH01-R02-101 Solid Tumors | trial_candidate: KSH01-TCRT Solid Tumors",
    "best_fit_trial_title": "KSX01-TCRT Injection Project in Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05811975",
    "best_urgency_trial_title": "KSX01-TCRT Injection Project in Solid Tumors",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "EARLY_PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05811975",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "TCRx Therapeutics Co.Ltd",
    "total_score": 12.0,
    "fit_score": 3.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05811975",
      "https://clinicaltrials.gov/study/NCT05580796",
      "https://clinicaltrials.gov/study/NCT05539833"
    ],
    "score_details": {
      "trial_count": 3,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Shenzhen Pregene Biopharma Co., Ltd.",
    "fit": 2.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 10.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myelo | trial_collaborator: Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease",
    "best_fit_trial_title": "A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06691685",
    "best_urgency_trial_title": "A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "EARLY_PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06691685",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Shenzhen Pregene Biopharma Co., Ltd.",
    "total_score": 10.0,
    "fit_score": 2.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06691685",
      "https://clinicaltrials.gov/study/NCT06497361"
    ],
    "score_details": {
      "trial_count": 2,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Shenzhen MagicRNA Biotechnology Co., Ltd",
    "fit": 2.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 10.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)",
    "best_fit_trial_title": "Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "NA",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06801119",
    "best_urgency_trial_title": "Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "NA",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06801119",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Shenzhen MagicRNA Biotechnology Co., Ltd",
    "total_score": 10.0,
    "fit_score": 2.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06801119"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Beijing Geekgene Technology Co., LTD",
    "fit": 2.0,
    "urgency": 2.0,
    "access": 0.0,
    "total": 10.0,
    "fit_reason": "immuno-oncology trial",
    "urgency_reason": "RECRUITING",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_candidate: a Single-arm, Single-center, Open Clinical Study",
    "best_fit_trial_title": "a Single-arm, Single-center, Open Clinical Study",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06431100",
    "best_urgency_trial_title": "a Single-arm, Single-center, Open Clinical Study",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06431100",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Beijing Geekgene Technology Co., LTD",
    "total_score": 10.0,
    "fit_score": 2.0,
    "urgency_score": 2.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06431100"
    ],
    "score_details": {
      "trial_count": 1,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "GSK",
    "fit": 1.0,
    "urgency": 0.0,
    "access": 0.0,
    "total": 4.0,
    "fit_reason": "no trials",
    "urgency_reason": "no trials and no relevant sec/patent signals",
    "urgency_source": "none",
    "trigger_summary": "",
    "best_fit_trial_title": null,
    "best_fit_trial_status": null,
    "best_fit_trial_phase": "",
    "best_fit_trial_url": null,
    "best_urgency_trial_title": null,
    "best_urgency_trial_status": null,
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": null,
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "GSK",
    "total_score": 4.0,
    "fit_score": 1.0,
    "urgency_score": 0.0,
    "access_score": 0.0,
    "evidence_links": [],
    "score_details": {
      "trial_count": 0,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "PPD, Part of Thermo Fisher Scientific",
    "fit": 1.0,
    "urgency": 0.0,
    "access": 0.0,
    "total": 2.0,
    "fit_reason": "no trials",
    "urgency_reason": "no trials and no relevant sec/patent signals",
    "urgency_source": "none",
    "trigger_summary": "trial_collaborator: Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell N",
    "best_fit_trial_title": null,
    "best_fit_trial_status": null,
    "best_fit_trial_phase": "",
    "best_fit_trial_url": null,
    "best_urgency_trial_title": null,
    "best_urgency_trial_status": null,
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": null,
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "PPD, Part of Thermo Fisher Scientific",
    "total_score": 2.0,
    "fit_score": 1.0,
    "urgency_score": 0.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06508931"
    ],
    "score_details": {
      "trial_count": 0,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "AbbVie",
    "fit": 1.0,
    "urgency": 0.0,
    "access": 0.0,
    "total": 2.0,
    "fit_reason": "no trials",
    "urgency_reason": "no trials and no relevant sec/patent signals",
    "urgency_source": "none",
    "trigger_summary": "trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and",
    "best_fit_trial_title": null,
    "best_fit_trial_status": null,
    "best_fit_trial_phase": "",
    "best_fit_trial_url": null,
    "best_urgency_trial_title": null,
    "best_urgency_trial_status": null,
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": null,
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "AbbVie",
    "total_score": 2.0,
    "fit_score": 1.0,
    "urgency_score": 0.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05660967",
      "https://clinicaltrials.gov/study/NCT04623541"
    ],
    "score_details": {
      "trial_count": 0,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Daiichi Sankyo",
    "fit": 1.0,
    "urgency": 0.0,
    "access": 0.0,
    "total": 2.0,
    "fit_reason": "no trials",
    "urgency_reason": "no trials and no relevant sec/patent signals",
    "urgency_source": "none",
    "trigger_summary": "trial_collaborator: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)",
    "best_fit_trial_title": null,
    "best_fit_trial_status": null,
    "best_fit_trial_phase": "",
    "best_fit_trial_url": null,
    "best_urgency_trial_title": null,
    "best_urgency_trial_status": null,
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": null,
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Daiichi Sankyo",
    "total_score": 2.0,
    "fit_score": 1.0,
    "urgency_score": 0.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04471727"
    ],
    "score_details": {
      "trial_count": 0,
      "sec_matched": 0,
      "patent_matched": 0
    }
  },
  {
    "account_name": "Takeda Development Center Americas, Inc.",
    "fit": 1.0,
    "urgency": 0.0,
    "access": 0.0,
    "total": 2.0,
    "fit_reason": "no trials",
    "urgency_reason": "no trials and no relevant sec/patent signals",
    "urgency_source": "none",
    "trigger_summary": "trial_collaborator: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myel",
    "best_fit_trial_title": null,
    "best_fit_trial_status": null,
    "best_fit_trial_phase": "",
    "best_fit_trial_url": null,
    "best_urgency_trial_title": null,
    "best_urgency_trial_status": null,
    "best_urgency_trial_phase": "",
    "best_urgency_trial_url": null,
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": []
    },
    "target_roles": [
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development",
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)"
    ],
    "company": "Takeda Development Center Americas, Inc.",
    "total_score": 2.0,
    "fit_score": 1.0,
    "urgency_score": 0.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06980480"
    ],
    "score_details": {
      "trial_count": 0,
      "sec_matched": 0,
      "patent_matched": 0
    }
  }
]